08:00 , Nov 14, 2013 |  BC Innovations  |  Cover Story

Trends with benefits

The FDA set up its adverse event database decades ago to capture the side effects of marketed drugs, but a group from the Icahn School of Medicine at Mount Sinai has now exploited the millions...
07:00 , Oct 15, 2012 |  BioCentury  |  Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Clinical News

Actos pioglitazone HCL endocrine data

A meta-analysis of data from 33,040 Type II diabetes patients enrolled in the ADVANCE, UKPDS, PROactive, VADT and ACCORD trials showed that intensive glycemic control produced a 17% reduction in events of non-fatal myocardial infarction...
07:00 , Sep 15, 2008 |  BC Week In Review  |  Clinical News

Diamicron MR gliclazide: Additional Phase III data

Additional data from the placebo-controlled, international Phase III ADVANCE trial in 11,140 patients showed that Diamicron MR gliclazide plus perindopril/indapamide reduced the risk of death from heart disease by 24% (p=0.04) and the risk of...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Clinical News

Diamicron MR gliclazide: Phase III data

Researchers reported additional data from the international Phase III ADVANCE trial in 11,140 patients that compared intensive glycemic control with Diamicron and other drugs (target HbA1c <=6.5%) with standard treatment. The study’s primary endpoint was...
08:00 , Feb 25, 2008 |  BC Week In Review  |  Clinical News

Diamicron MR gliclazide: Phase III data

Interim data from the international Phase III ADVANCE trial in 11,140 patients showed that treatment with Diamicron MR gliclazide, for intensive glycemic control (target HbA1c <6.5%), did not increase the risk of death after >5...